Phase 2 N=50 A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia
Hypercholesterolemia
Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) — 8; 10; 8; 11 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=162 Acetaminophen Versus IV Hydromorphone for Pain in the Elderly in the ED
Acute Pain
Primary: Clinical Improvement in NRS Pain Score — 62; 63 Participants
Phase 2 N=26 Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma
Stage IV Melanoma · Stage III Melanoma · Advanced Melanoma
Primary: Maximally Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) of Pembrolizumab — 200 mg
Phase 2 N=37 A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Pancreatic Cancer (Unresectable)
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 24; 12; 9; 6 Participants
Phase 2 N=861 A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
Chronic Kidney Disease
Primary: Urinary Albumin to Creatinine Ratio (uACR) (mg/g) Change From Baseline at 6 Months (Visit 8), Repeated Measures Mixed Model (MMRM) — 0.8300; 1.043; 0.8369; 0.8499 mg/g…
Phase 2 N=40 Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients
Acute Myeloid Leukemia
Primary: Maximal Tolerable Dose of Pembrolizumab for Cohort 1 — 200 mg
Phase 2 N=158 A Clinical Trial to Assess Subjects With Dry Eye Disease.
Dry Eye
Primary: Conjunctival Redness Assessed Via Digital Photography Over 90 Minutes in the Dry Eye Chamber — 0.066; 0.183 units on a scale
Phase 2 N=173 The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Leukemia, Myeloid, Chronic
Primary: Number of Patients With Chronic Myeloid Leukemia (CML) Who Develop Molecular Recurrence After Discontinuing TKIs. — 0; 4; 12; 11 Participants
Phase 2 N=23 Effect of CT1812 Treatment on Brain Synaptic Density
Alzheimer Disease
Primary: Number of TEAEs, Related TEAEs, SAEs, and Related SAEs — 7; 8; 6; 21 Participants
Phase 2 N=87 Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis (NASH)
Primary: MRI-PDFF Change From Baseline to Week 14 — -1.25; -0.90; 0.90 Percentage of hepatic fat fraction
Phase 2 N=180 Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
Osteoarthritis, Knee · Osteoarthritis, Hip
Primary: Change From Baseline in Peroneal Motor Nerve Conduction Velocity at Week 16 — -0.2; 0.2 m/sec — p=0.4192
Phase 2 N=114 Impact of Periodontal Therapy on Patients With Diabetes
Diabetes Mellitus, Type II · Periodontitis
Primary: Change in Probing Pocket Depth at the 6-month Post-SRP Completed at Baseline — -0.25; -0.18 mm — p=0.16
Phase 2 N=169 Study of VVN001 Ophthalmic Solution in Dry Eye Disease
Dry Eye
Primary: Inferior Corneal Fluorescein Staining — -0.69; -.97; -0.72 score on a scale
Phase 2 N=25 A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
Chikungunya Virus
Primary: CHIKV SNA (Serum Neutralizing Antibody) Seroresponse Rate at Day 22 — 100.0 Percentage of participants
Phase 2 N=58 Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer
Pancreatic Cancer
Primary: Distant Metastasis Free Survival (DMFS) — 9.8 months